LMNX - Luminex Languishing In A Sentiment Grey Zone

• Like most other manufacturers of diagnostic systems and test panels, Luminex has seen sales surge on COVID-19 pandemic demand.
• The new VERIGENE II platform offers improved system performance over the older generation, but menu expansion will be critical.
• The older ARIES platform continues to drive growth opportunities, with management looking to double test production capacity and drive sustained long-term sales from pandemic-fueled system placements.
• Recent rumors of M&A interest in Luminex make sense given the company's credible position/scale in molecular diagnostics but also a long-term history of under-executing.
• As is, Luminex looks undervalued and could have upside into the $40s, but it occupies a tough space between growth and quality, and it has frustrated many analysts and investors over the years.

For further details see: